About Sinovac Biotech (NASDAQ:SVA)
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biopharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:SVA
- CUSIP: N/A
- Web: www.sinovac.com
- Market Cap: $402.19 million
- Outstanding Shares: 56,968,000
- 50 Day Moving Avg: $6.95
- 200 Day Moving Avg: $6.25
- 52 Week Range: $4.60 - $7.16
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 141.20
- P/E Growth: 0.00
- Annual Revenue: $64.02 million
- Price / Sales: 6.28
- Book Value: $2.02 per share
- Price / Book: 3.50
- Average Volume: 80,520 shs.
- Short Ratio: 1.53
Frequently Asked Questions for Sinovac Biotech (NASDAQ:SVA)
What is Sinovac Biotech's stock symbol?
Sinovac Biotech trades on the NASDAQ under the ticker symbol "SVA."
How were Sinovac Biotech's earnings last quarter?
Sinovac Biotech, Ltd. (NASDAQ:SVA) posted its earnings results on Tuesday, August, 23rd. The company reported ($0.15) earnings per share for the quarter. The company earned $1.38 billion during the quarter, compared to analysts' expectations of $18.49 billion. During the same period in the prior year, the business posted $0.02 EPS. View Sinovac Biotech's Earnings History.
Who are some of Sinovac Biotech's key competitors?
Some companies that are related to Sinovac Biotech include Syros Pharmaceuticals (SYRS), ChemoCentryx (CCXI), Syndax Pharmaceuticals (SNDX), Synlogic (SYBX), Mereo BioPharma Group PLC (MPH), Strongbridge Biopharma PLC (SBBP), Fortress Biotech (FBIO), Kamada (KMDA), Peregrine Pharmaceuticals (PPHM), Kadmon Holdings (KDMN), Vericel Corp (VCEL), MediWound (MDWD), KalVista Pharmaceuticals (KALV), Alimera Sciences (ALIM), VIVUS (VVUS), Opiant Pharmaceuticals (OPNT), Chiasma (CHMA) and Cardiome Pharma Corporation (CRME).
Who are Sinovac Biotech's key executives?
Sinovac Biotech's management team includes the folowing people:
- Weidong Yin, Chairman of the Board, President, Chief Executive Officer, Secretary
- Nan Wang, Chief Financial Officer
- Ming Xia, Vice President - Sales and Marketing of Sinovac Beijing
- Simon J. Anderson, Independent Director
- Jue Lee, Independent Director
- Yuk Lam Lo, Independent Director
- Meng Mei, Independent Director
Who owns Sinovac Biotech stock?
Who sold Sinovac Biotech stock? Who is selling Sinovac Biotech stock?
How do I buy Sinovac Biotech stock?
Shares of Sinovac Biotech can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sinovac Biotech's stock price today?
MarketBeat Community Rating for Sinovac Biotech (NASDAQ SVA)MarketBeat's community ratings are surveys of what our community members think about Sinovac Biotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Sinovac Biotech stock can currently be purchased for approximately $7.06.
Consensus Ratings for Sinovac Biotech (NASDAQ:SVA) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for Sinovac Biotech (NASDAQ:SVA)
Analysts' Ratings History for Sinovac Biotech (NASDAQ:SVA)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Sinovac Biotech (NASDAQ:SVA)Earnings History by Quarter for Sinovac Biotech (NASDAQ SVA)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/28/2016||Q316||$0.05||$0.06||$16.76 million||$28.74 million||View||N/A|
|8/23/2016||Q2||($0.15)||$18.49 billion||$1.38 billion||View||Listen|
|11/11/2015||Q315||($0.02)||($0.03)||$27.10 million||$16.80 million||View||Listen|
|8/12/2015||Q215||($0.01)||$0.04||$15.70 million||$18.50 million||View||Listen|
|5/15/2015||Q115||$0.02||($0.04)||$12.70 million||$9.27 million||View||N/A|
|4/20/2015||Q414||$0.01||$0.02||$14.10 million||$22.90 million||View||N/A|
|8/14/2014||Q214||$0.01||($0.04)||$17.20 million||$12.10 million||View||N/A|
|3/19/2014||Q4 13||($0.01)||$0.10||$18.75 million||$22.90 million||View||N/A|
|11/15/2012||Q312||($0.03)||($0.06)||$12.35 million||$14.30 million||View||N/A|
Earnings Estimates for Sinovac Biotech (NASDAQ:SVA)
Current Year EPS Consensus Estimate: $-0.05 EPS
Next Year EPS Consensus Estimate: $0.05 EPS
Dividend History for Sinovac Biotech (NASDAQ:SVA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Sinovac Biotech (NASDAQ:SVA)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Sinovac Biotech (NASDAQ:SVA)
Latest Headlines for Sinovac Biotech (NASDAQ:SVA)
Loading headlines, please wait.
Sinovac Biotech (SVA) Chart for Tuesday, October, 24, 2017